# Improvement Roadmap & Next Steps

## Current Status Summary

### ✅ What's Working:
- **Blood transcriptomics ML**: AUC = 0.968 (excellent!)
- **EC dysfunction scoring**: Successfully calculated from real tissue data
- **Multi-omics framework**: Established and functional
- **Novel biological findings**: Spermine pathway, novel genes

### ⚠️ Current Limitation:
- **Multi-omics integration**: AUC = 0.528 (essentially random)
- **Root cause**: Only EC dysfunction available; missing PRS, blood signature, clinical data

---

## PRIORITY 1: IMMEDIATE IMPROVEMENTS (Data Available Now)

### 1.1 Improve EC Dysfunction Score Predictive Power

**Current Issue**: EC dysfunction alone has limited predictive power (AUC = 0.528)

**Actions:**
1. **Add more EC markers** to the dysfunction score
   - Current: 13 markers
   - Target: 20-30 markers from literature
   - Include: E-selectin, P-selectin, eNOS, iNOS, ADAMTS13

2. **Refine weighting scheme**
   - Current: Simple weighted sum
   - Improve: Use literature-based effect sizes
   - Add: Interaction terms between markers

3. **Add EC marker ratios**
   - ANGPT2/ANGPT1 ratio (more informative than absolute)
   - ICAM1/VCAM1 ratio
   - Pro-inflammatory/anti-inflammatory balance

**Expected Impact**: AUC improvement from 0.528 → 0.60-0.65

**Implementation Time**: 1-2 days

---

### 1.2 Extract More Features from Tissue Expression

**Current Issue**: Only using EC dysfunction score from tissue data

**Actions:**
1. **Calculate additional tissue-based scores:**
   - **Inflammation score**: Mean of IL-6, TNF-α, IL-1β, CRP
   - **ECM remodeling score**: MMP-9, TIMP-1, COL3A1, COL1A1
   - **Smooth muscle score**: ACTA2, MYH11, TAGLN
   - **Apoptosis score**: BAX, BCL2, CASP3
   - **Oxidative stress score**: NOX4, SOD2, CAT

2. **Pathway activity scores:**
   - Use pathway enrichment results
   - Calculate pathway activity from gene set expression
   - Top pathways: Spermine synthase, inflammation, ECM

3. **Gene signature scores:**
   - Top DE genes signature (SMS, Ccd, CPXM2, MARCO)
   - Rupture-specific gene signature

**Expected Impact**: AUC improvement from 0.528 → 0.65-0.75

**Implementation Time**: 2-3 days

---

### 1.3 Improve Feature Engineering

**Current Issue**: Simple mean/weighted sum approaches

**Actions:**
1. **Non-linear transformations:**
   - Log transformations
   - Polynomial features
   - Interaction terms

2. **Dimensionality reduction:**
   - PCA on expression data
   - Extract top principal components
   - Use as features

3. **Feature selection:**
   - Remove redundant features
   - Select most predictive markers
   - Use LASSO/elastic net for selection

**Expected Impact**: AUC improvement from 0.528 → 0.60-0.70

**Implementation Time**: 2-3 days

---

## PRIORITY 2: DATA ACQUISITION (Short-term, 1-4 weeks)

### 2.1 Obtain Clinical Metadata

**Current Issue**: Clinical_Score = 0 (no clinical data)

**Actions:**
1. **Extract from GEO metadata:**
   - Check GSE122897 series matrix for clinical variables
   - Age, sex, hypertension, smoking status
   - Aneurysm size, location, morphology

2. **Contact data authors:**
   - Email corresponding authors
   - Request clinical metadata
   - Many authors share upon request

3. **Use published clinical data:**
   - Check supplementary materials
   - Extract from publication tables
   - Cross-reference with sample IDs

**Expected Impact**: AUC improvement from 0.528 → 0.60-0.70 (with clinical)

**Implementation Time**: 1-2 weeks

---

### 2.2 Match Blood and Tissue Samples

**Current Issue**: Blood_RNA_Score = 0 (no matching samples)

**Actions:**
1. **Find overlapping samples:**
   - Check if any GSE122897 samples have matching GSE159610 samples
   - Same patient IDs or metadata matching

2. **Use blood signature on tissue:**
   - Apply blood signature genes to tissue expression
   - Calculate signature score from tissue data
   - May not be perfect but better than 0

3. **Cross-dataset imputation:**
   - Use tissue expression to estimate blood signature
   - Based on correlation patterns
   - Literature-based relationships

**Expected Impact**: AUC improvement from 0.528 → 0.65-0.75

**Implementation Time**: 1-2 weeks

---

### 2.3 Obtain Genotype Data for PRS

**Current Issue**: PRS excluded (requires genotype data)

**Actions:**
1. **Check for available genotype data:**
   - Look for GWAS datasets with overlapping samples
   - Check dbGaP for available data
   - Contact authors for genotype access

2. **Use proxy PRS:**
   - Calculate PRS from available GWAS summary stats
   - Use population-level risk scores
   - Literature-based risk estimates

3. **Alternative: Use published PRS:**
   - If PRS calculated in other studies
   - Use as external validation
   - Compare with our model

**Expected Impact**: AUC improvement from 0.528 → 0.70-0.80 (with PRS)

**Implementation Time**: 2-4 weeks

---

## PRIORITY 3: METHODOLOGICAL IMPROVEMENTS (1-2 weeks)

### 3.1 Advanced Machine Learning Models

**Current Issue**: Gradient boosting with limited features

**Actions:**
1. **Try different algorithms:**
   - Deep learning (neural networks)
   - Ensemble methods (stacking, voting)
   - Support vector machines with RBF kernel
   - XGBoost, LightGBM

2. **Hyperparameter optimization:**
   - Grid search / random search
   - Bayesian optimization
   - Cross-validation based tuning

3. **Feature engineering with ML:**
   - Autoencoder for feature extraction
   - Feature selection with ML
   - Transfer learning approaches

**Expected Impact**: AUC improvement from 0.528 → 0.60-0.70

**Implementation Time**: 1 week

---

### 3.2 Better Cross-Validation Strategy

**Current Issue**: Standard 5-fold CV may not be optimal

**Actions:**
1. **Stratified cross-validation:**
   - Ensure balanced classes in each fold
   - Account for sample size differences

2. **Nested cross-validation:**
   - Outer CV for model evaluation
   - Inner CV for hyperparameter tuning
   - Prevents overfitting

3. **Leave-one-out CV:**
   - Given small sample size (n=60)
   - More robust for small datasets

**Expected Impact**: More reliable performance estimates

**Implementation Time**: 2-3 days

---

### 3.3 Address Class Imbalance

**Current Issue**: 38 unruptured vs. 22 ruptured (imbalanced)

**Actions:**
1. **Resampling techniques:**
   - SMOTE (Synthetic Minority Oversampling)
   - Undersampling majority class
   - Combination approaches

2. **Class weights:**
   - Adjust class weights in models
   - Penalize misclassification of minority class
   - Cost-sensitive learning

3. **Ensemble methods:**
   - Train multiple models on balanced subsets
   - Combine predictions
   - Improve minority class prediction

**Expected Impact**: Better prediction of rupture cases

**Implementation Time**: 3-5 days

---

## PRIORITY 4: VALIDATION & ROBUSTNESS (2-4 weeks)

### 4.1 External Validation

**Actions:**
1. **Find independent datasets:**
   - Search GEO for other aneurysm datasets
   - Check for ruptured vs. unruptured comparisons
   - Use as external validation

2. **Cross-dataset validation:**
   - Train on GSE122897, test on other dataset
   - Or vice versa
   - Assess generalizability

3. **Bootstrap validation:**
   - Resample with replacement
   - Assess stability of results
   - Confidence intervals

**Expected Impact**: Validate model generalizability

**Implementation Time**: 2-3 weeks

---

### 4.2 Biological Validation

**Actions:**
1. **Literature validation:**
   - Check if top genes are in published studies
   - Validate pathway associations
   - Compare with known mechanisms

2. **Functional enrichment:**
   - More comprehensive pathway analysis
   - Gene ontology enrichment
   - Network analysis

3. **Mechanistic interpretation:**
   - Understand why EC dysfunction predicts rupture
   - Link to biological processes
   - Generate testable hypotheses

**Expected Impact**: Strengthen biological interpretation

**Implementation Time**: 1-2 weeks

---

## PRIORITY 5: COMPREHENSIVE ANALYSIS (2-3 weeks)

### 5.1 Integrate All Available Data

**Actions:**
1. **Combine all tissue-based features:**
   - EC dysfunction score
   - Inflammation score
   - ECM remodeling score
   - Pathway activity scores
   - Top DE gene signature

2. **Add clinical features** (when available):
   - Age, sex, hypertension
   - Aneurysm size, location
   - Previous SAH

3. **Create comprehensive feature set:**
   - 20-30 features total
   - All from real data
   - Properly normalized

**Expected Impact**: AUC improvement from 0.528 → 0.70-0.80

**Implementation Time**: 1 week

---

### 5.2 Advanced Integration Methods

**Actions:**
1. **Multi-view learning:**
   - Treat each omics layer as a "view"
   - Learn shared representations
   - Integrate at representation level

2. **Graph-based integration:**
   - Create gene-gene interaction networks
   - Integrate across networks
   - Use graph neural networks

3. **Bayesian integration:**
   - Probabilistic modeling
   - Uncertainty quantification
   - Hierarchical models

**Expected Impact**: Better integration, AUC = 0.75-0.85

**Implementation Time**: 2-3 weeks

---

## IMMEDIATE ACTION PLAN (Next 1-2 Weeks)

### Week 1: Quick Wins
1. **Day 1-2**: Add more EC markers and refine dysfunction score
2. **Day 3-4**: Calculate inflammation, ECM, and pathway scores from tissue
3. **Day 5**: Improve feature engineering (non-linear, interactions)
4. **Day 6-7**: Try advanced ML models (XGBoost, neural networks)

**Expected Outcome**: AUC improvement from 0.528 → 0.65-0.70

### Week 2: Data Acquisition
1. **Day 1-3**: Extract clinical metadata from GEO/supplementary
2. **Day 4-5**: Contact authors for additional data
3. **Day 6-7**: Apply blood signature to tissue data (if possible)

**Expected Outcome**: Add clinical features, improve to AUC = 0.70-0.75

---

## LONG-TERM GOALS (1-3 Months)

### Month 1: Complete Data Integration
- Obtain all missing data (clinical, PRS, matched samples)
- Integrate all features
- Optimize model
- **Target**: AUC = 0.75-0.85

### Month 2: Validation
- External validation on independent datasets
- Biological validation
- Robustness testing
- **Target**: Validated AUC = 0.70-0.80

### Month 3: Publication
- Write manuscript
- Generate figures
- Submit for publication
- **Target**: Publication-ready manuscript

---

## SPECIFIC CODE IMPLEMENTATIONS

### Implementation 1: Enhanced EC Dysfunction Score

```python
# Add more EC markers
EXTENDED_EC_MARKERS = {
    # Existing 13 markers +
    'SELE': 'E-selectin - leukocyte adhesion',
    'SELP': 'P-selectin - platelet adhesion',
    'NOS3': 'eNOS - endothelial nitric oxide',
    'NOS2': 'iNOS - inducible nitric oxide',
    'ADAMTS13': 'Von Willebrand factor cleaving protease',
    'FLT1': 'VEGFR1 - angiogenesis',
    'FLT4': 'VEGFR3 - lymphangiogenesis',
    # ... more markers
}

# Refined weighting based on literature
WEIGHTS = {
    'ANGPT2': 1.2,  # Strong predictor
    'ICAM1': 1.1,
    'VCAM1': 1.1,
    'VWF': -0.8,  # Downregulated = dysfunction
    # ... refined weights
}
```

### Implementation 2: Additional Tissue Scores

```python
# Inflammation score
INFLAMMATION_GENES = ['IL6', 'TNF', 'IL1B', 'CRP', 'CXCL8']
inflammation_score = expr_df[INFLAMMATION_GENES].mean(axis=1)

# ECM remodeling score
ECM_GENES = ['MMP9', 'TIMP1', 'COL3A1', 'COL1A1', 'ELN']
ecm_score = expr_df[ECM_GENES].mean(axis=1)

# Top DE gene signature
TOP_DE_GENES = ['SMS', 'Ccd', 'CPXM2', 'MARCO']
de_signature = expr_df[TOP_DE_GENES].mean(axis=1)
```

### Implementation 3: Advanced ML Models

```python
from xgboost import XGBClassifier
from lightgbm import LGBMClassifier
from sklearn.neural_network import MLPClassifier

# Try XGBoost
xgb_model = XGBClassifier(
    n_estimators=200,
    max_depth=5,
    learning_rate=0.05,
    subsample=0.8,
    colsample_bytree=0.8
)

# Try LightGBM
lgbm_model = LGBMClassifier(
    n_estimators=200,
    max_depth=5,
    learning_rate=0.05
)

# Try Neural Network
nn_model = MLPClassifier(
    hidden_layer_sizes=(50, 25),
    max_iter=1000,
    alpha=0.01
)
```

---

## SUCCESS METRICS

### Short-term (1-2 weeks):
- ✅ AUC > 0.65 (from current 0.528)
- ✅ At least 5 informative features
- ✅ Model stability (CV std < 0.15)

### Medium-term (1 month):
- ✅ AUC > 0.75
- ✅ All data layers integrated
- ✅ External validation completed

### Long-term (3 months):
- ✅ AUC > 0.80
- ✅ Publication-ready results
- ✅ Manuscript submitted

---

## RESOURCES NEEDED

### Data:
- Clinical metadata (age, sex, hypertension, etc.)
- Genotype data (for PRS)
- Matched blood-tissue samples

### Computational:
- Current setup is sufficient
- May need more RAM for advanced ML models

### Time:
- Quick wins: 1 week
- Data acquisition: 2-4 weeks
- Complete integration: 1-2 months

---

## CONCLUSION

**Current Status**: Framework established, but limited by data availability (AUC = 0.528)

**Immediate Next Steps**:
1. Enhance EC dysfunction score (add markers, refine weights)
2. Extract more features from tissue expression
3. Try advanced ML models
4. Acquire clinical metadata

**Expected Improvement**: AUC from 0.528 → 0.65-0.75 in 1-2 weeks

**Long-term Goal**: AUC = 0.80+ with complete data integration

**Key Message**: The framework is sound - we just need more features and data to reach the full potential!






